Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ORIC

Oric Pharmaceuticals

ORIC Lead: Phase 3 1 Biotech Distilled article ↓ 11 filings & releases ↓ Cash $37.5M (Jun 30, 2026) ↓ 1 verdict ↓
Oncology Small Molecule

Market cap $914M 103.7M shares (10-Q, Jul 27, 2026) × $8.82 close Nov 6, 2026

Most recent annual filing: 2026-02-23

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Rinzimetostat readout2H 2026Rinzimetostat readout, 2H 2026, notable
  2. ORIC corporate updateNov 2026ORIC corporate update, Nov 2026, routine
  3. Enozertinib trial start1H 2027Enozertinib trial start, 1H 2027, routine
  4. Rinzimetostat Ph3 start2027Rinzimetostat Ph3 start, 2027, routine
  5. Mevrometostat MEVPRO-1 Pfizer toplineFeb 2027Mevrometostat MEVPRO-1 Pfizer topline, Feb 2027, thesis-defining
  6. Zipalertinib Taiho-Cullinan PDUFA dateFeb 27, 2027Zipalertinib Taiho-Cullinan PDUFA date, Feb 27, 2027, material
  7. Enozertinib EGFR Ph3 readoutMid-2027Enozertinib EGFR Ph3 readout, Mid-2027, notable
  8. Mevrometostat MEVPRO-2 Pfizer topline4Q 2027Mevrometostat MEVPRO-2 Pfizer topline, 4Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Capital (as filed)

Cash
$37.5M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$227M Jun 30, 2026
Long-term investments
$123M Jun 30, 2026
Operating cash flow
−$31.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$388M cash, runway 2H 2028 per the deep dive of Nov 3, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Oric Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-11-04 Watch ORIC Pharmaceuticals (ORIC) - Scientific Deep Dive for Rinzimetostat, Enozertinib and Pipeline Products ORIC has two well-chosen molecules and a clean prostate licence at a reasonable enterprise value, but its prostate efficacy case rests on 18 patients at 4.9 months and the class-validating readout belongs to Pfizer in ~February 2027, making it prudent to wait for the class answer and a mature dataset before paying.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (11)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)